Epigenetic therapy reverting aberrant acetylation or methylation offers the possibility to target preferentially tumor cells and to preserve normal cells. Combination epigenetic therapy may further improve the effect of individual drugs. We investigated combined action of demethylating agent decitabine and histone deacetylase inhibitor SAHA (Vorinostat) on different leukemic cell lines in comparison with peripheral blood lymphocytes. Large decrease of viability, as well as huge p21WAF1 induction, reactive oxygen species formation, and apoptotic features due to combined decitabine and SAHA action were detected in leukemic cell lines irrespective of their p53 status, while essentially no effect was observed in response to the combined drug action in normal peripheral blood lymphocytes of healthy donors. p53-dependent apoptotic pathway was demonstrated to participate in the wtp53 CML-T1 leukemic cell line response, while significant influence of reactive oxygen species on viability decrease has been detected in p53-null HL-60 cell line.

Institute of Hematology and Blood Transfusion Prague Czech Republic

See more in PubMed

Sollars VE. Epigenetic modification as an enabling mechanism for leukemic transformation. Frontiers in Bioscience. 2005;10(2):1635–1646. PubMed

Chan TA, Baylin SB. Epigenetic biomarkers. Current Topics in Microbiology and Immunology. 2012;355:189–216. PubMed

Hatziapostolou M, Iliopoulos D. Epigenetic aberrations during oncogenesis. Cellular and Molecular Life Sciences. 2011;68(10):1681–1702. PubMed PMC

Ganesan A, Nolan L, Crabb SJ, Packham G. Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery. Current Cancer Drug Targets. 2009;9(8):963–981. PubMed

Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2009;31(1):27–36.bgp220 PubMed PMC

Easwaran HP, Schermelleh L, Leonhardt H, Cardoso MC. Replication-independent chromatin loading of Dnmt1 during G2 and M phases. The EMBO Reports. 2004;5(12):1181–1186. PubMed PMC

Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99(3):247–257. PubMed

Länger F, Dingemann J, Kreipe H, Lehmann U. Up-regulation of DNA methyltransferases DNMT1, 3A, and 3B in myelodysplastic syndrome. Leukemia Research. 2005;29(3):325–329. PubMed

Mizuno S, Chijiwa T, Okamura T, et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood. 2001;97(5):1172–1179. PubMed

Riva L, Luzi L, Pelicci PG. Genomics of acute myeloid leukemia: the next generation. Frontiers in Oncology. 2012;2, article 40 PubMed PMC

Jurkowska RZ, Jurkowski TP, Jeltsch A. Structure and function of mammalian DNA methyltransferases. ChemBioChem. 2011;12(2):206–222. PubMed

Estève P, Chin HG, Pradhan S. Human maintenance DNA (cytosine-5)-methyltransferase and p53 modulate expression of p53-repressed promoters. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(4):1000–1005. PubMed PMC

Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. Journal of Clinical Oncology. 2002;20(10):2429–2440. PubMed

Yan P, Frankhouser D, Murphy M, et al. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood. 2012;120:2466–2474. PubMed PMC

Nieto M, Samper E, Fraga MF, González De Buitrago G, Esteller M, Serrano M. The absence of p53 is critical for the induction of apoptosis by 5-aza-2′-deoxycytidine. Oncogene. 2004;23(3):735–743. PubMed

Baylin SB, Ohm JE. Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction? Nature Reviews Cancer. 2006;6(2):107–116. PubMed

Pandolfi PP. Histone deacetylases and transcriptional therapy with their inhibitors. Cancer Chemotherapy and Pharmacology. 2001;48(supplement 1):S17–S19. PubMed

Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26(37):5541–5552. PubMed

Bellucci L, Dalvai M, Kocanova S, Moutahir F, Bystricky K. Activation of p21 by HDAC inhibitors requires acetylation of H2A.Z. PLoS One. 2013;8e54102 PubMed PMC

Zhou Q, Dalgard CL, Wynder C, Doughty ML. Histone deacetylase inhibitors SAHA and sodium butyrate block G1-to-S cell cycle progression in neurosphere formation by adult subventricular cells. BMC Neuroscience. 2011;12, article 50 PubMed PMC

Wang H, Zhou W, Zheng Z, et al. The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage. DNA Repair. 2012;11(2):146–156. PubMed

Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. Cell. 2008;133(4):612–626. PubMed PMC

Yamaguchi H, Woods NT, Piluso LG, et al. p53 acetylation is crucial for its transcription-independent proapoptotic functions. The Journal of Biological Chemistry. 2009;284(17):11171–11183. PubMed PMC

Qin W, Leonhardt H, Pichler G. Regulation of DNA methyltransferase 1 by interactions and modifications. Nucleus (Austin, Tex.) 2011;2(5):392–402. PubMed

Chen M, Liao WS-L, Lu Z, et al. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer. 2011;117(19):4424–4438. PubMed PMC

Zhou Q, Agoston AT, Atadja P, Nelson WG, Davidson NE. Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Molecular Cancer Research. 2008;6(5):873–883. PubMed PMC

Scott SA, Dong W, Ichinohasama R, et al. 5-Aza-2′-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation. Leukemia Research. 2006;30(1):69–76. PubMed

Yang D, Torres CM, Bardhan K, Zimmerman M, McGaha TL, Liu K. Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to fas ligand-induced apoptosis in vitro and tumor suppression in vivo. Journal of Immunology. 2012;188(9):4441–4449. PubMed PMC

Brodská B, Holoubek A. Generation of reactive oxygen species during apoptosis induced by DNA-damaging agents and/or histone deacetylase inhibitors. Oxidative Medicine and Cellular Longevity. 2011;2011:7 pages.253529 PubMed PMC

Brodská B, Otevřelová P, Holoubek A. Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA. Molecular and Cellular Biochemistry. 2011;350(1-2):71–80. PubMed

Kalousek I, Brodska B, Otevrelova P, Röselova P. Actinomycin D upregulates proapoptotic protein Puma and downregulates Bcl-2 mRNA in normal peripheral blood lymphocytes. Anti-Cancer Drugs. 2007;18(7):763–772. PubMed

Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. International Journal of Cancer. 2008;123(1):8–13. PubMed

Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nature Biotechnology. 2012;30:679–692. PubMed

Lee JH, Pidaparti RM, Atkinson GM, Moorthy RS. Design of an implantable device for ocular drug delivery. Journal of Drug Delivery. 2012;2012:8 pages.527516 PubMed PMC

Held MA, Langdon CG, Platt JT, et al. Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discovery. 2013;3:52–67. PubMed PMC

Aketa H, Tatsumi T, Kohga K, et al. The combination therapy of alpha-galactosylceramide and 5-fluorouracil showed antitumor effect synergistically against liver tumor in mice. International Journal of Cancer. 2013 PubMed

Xu L, Qin Y, Huang J, et al. Effect of rapamycin-induced tumor vessel thrombosis combined with docetaxel in non-small-cell lung cancer. Anti-Cancer Drugs. 2013;24(4):406–414. PubMed

Gerullis H, Eimer C, Ecke TH, Georgas E, Arndt C, Otto T. Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy. Anti-Cancer Drugs. 2013;24(4):422–425. PubMed

Lee MS, Mamon HJ, Hong TS, et al. Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal Cancer. Oncologist. 2013;18(3):281–287. PubMed PMC

Kaushal GP, Shah SV. Non-apoptotic effects of antiapoptotic agent zVAD-fmk in renal injury. Kidney International. 2013;83(3):p. 531. PubMed PMC

Gui C-Y, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(5):1241–1246. PubMed PMC

Ju R, Muller MT. Histone deacetylase inhibitors activate p21WAF1 expression via ATM. Cancer Research. 2003;63(11):2891–2897. PubMed

Link PA, Baer MR, James SR, Jones DA, Karpf AR. P53-inducible ribonucleotide reductase (P53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. Cancer Research. 2008;68(22):9358–9366. PubMed PMC

Masgras I, Carrera S, De Verdier PJ, et al. Reactive oxygen species and mitochondrial sensitivity to oxidative stress determine induction of cancer cell death by p21. The Journal of Biological Chemistry. 2012;287(13):9845–9854. PubMed PMC

Passos JF, Nelson G, Wang C, et al. Feedback between p21 and reactive oxygen production is necessary for cell senescence. Molecular Systems Biology. 2010;6, article 347 PubMed PMC

Vijayaraghavalu S, Dermawan JK, Cheriyath V, Labhasetwar V. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest. Molecular Pharmacology. 2013;10:337–352. PubMed PMC

Lu T, Finkel T. Free radicals and senescence. Experimental Cell Research. 2008;314(9):1918–1922. PubMed PMC

Stein GH, Drullinger LF, Soulard A, Dulić V. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Molecular and Cellular Biology. 1999;19(3):2109–2117. PubMed PMC

Mao Z, Ke Z, Gorbunova V, Seluanov A. Replicatively senescent cells are arrested in G1 and G2 phases. Aging. 2012;4:431–435. PubMed PMC

Schwarze SR, Fu VX, Desotelle JA, Kenowski ML, Jarrard DF. The identification of senescence-specific genes during the induction of senescence in prostate cancer cells. Neoplasia. 2005;7(9):816–823. PubMed PMC

Amatori S, Bagaloni I, Viti D, Fanelli M. Premature senescence induced by DNA demethylating agent (Decitabine) as therapeutic option for malignant pleural mesothelioma. Lung Cancer. 2011;71(1):113–115. PubMed

Xu W, Perez G, Ngo L, Gui C, Marks PA. Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. Cancer Research. 2005;65(17):7832–7839. PubMed

Renault TT, Teijido O, Antonsson B, Dejean LM, Manon S. Regulation of Bax mitochondrial localization by Bcl-2 and Bcl-x(L): keep your friends close but your enemies closer. The International Journal of Biochemistry & Cell Biology. 2013;45:64–67. PubMed

Decitabine and SAHA-induced apoptosis is accompanied by survivin downregulation and potentiated by ATRA in p53-deficient cells